针对克罗恩病的黏膜愈合
Targeting mucosal healing in Crohn's disease.
作者信息
Kakkar Aarti, Wasan Sharmeel K, Farraye Francis A
机构信息
Dr. Kakkar is a Fellow in Gastroenterology, Dr. Wasan is a Clinical Instructor of Medicine, and Dr. Farraye is a Professor of Medicine and Clinical Director of the Section of Gastroenterology at Boston University School of Medicine in Boston, Massachusetts. Drs. Kakkar, Wasan, and Farraye are also affiliated with the Section of Gastroenterology at Boston Medical Center in Boston, Massachusetts.
出版信息
Gastroenterol Hepatol (N Y). 2011 Jun;7(6):374-80.
The goal of medical treatment for Crohn's disease includes improving patients' quality of life while reducing the need for hospitalization and surgery. The current medical armamentarium includes 5-aminosalicylates, corticosteroids, immunomodulators, and biologic agents. In the past, response to treatment was measured by clinical improvement in symptoms; however, with the advent of disease-modifying medications, mucosal healing has emerged as an increasingly important goal of therapy. Mucosal healing, or endoscopic remission, is associated with increased rates of clinical remission, fewer hospitalizations, and fewer abdominal surgeries. Both the immunomodulator and biologic classes of medications are effective at inducing mucosal healing. Despite several limitations, mucosal healing has become a desirable and valid measure of disease activity.
克罗恩病的医学治疗目标包括提高患者的生活质量，同时减少住院和手术需求。目前的药物治疗手段包括5-氨基水杨酸类药物、皮质类固醇、免疫调节剂和生物制剂。过去，治疗反应通过症状的临床改善来衡量；然而，随着疾病缓解药物的出现，黏膜愈合已成为越来越重要的治疗目标。黏膜愈合，即内镜下缓解，与临床缓解率增加、住院次数减少和腹部手术减少相关。免疫调节剂和生物制剂这两类药物在诱导黏膜愈合方面均有效。尽管存在一些局限性，但黏膜愈合已成为一种理想且有效的疾病活动度衡量指标。
Zotero 插件